Clinical observation of transcatheter arterial chemoembolization combined with apatinib in patients with advanced hepatocellular carcinoma
Objective:To investigate the efficacy of transarterial chemoembolisation(TACE)combined with apatinib in the treatment of mid to late stage liver cancer patients,and its impacts on objective response rate,survival time,and immune function.Methods:A total of 100 patients with advanced liver cancer who received treatment in our hospital from January 2020 to June 2021 were selected as the study subjects.They were randomly divided into combined group and control group,50 cases in each group.The patients in the control group were treated with TACE on the basis of conventional treatment,and the patients in the combined group were treated with apatinib on the basis of the control group.The objective remission rate,survival time,immune function and adverse reactions were compared between the two groups after treatment.Results:After treatment,the objective response rate of the combination group(50.00%)was obviously higher than that of the control group(28.00%)(P＜0.05).Compared with the control group,the median overall survival time(OS)and median progression free survival time(PFS)in the combined group were obviously higher(P＜0.05).After treatment,the immune function indicators of the two groups were compared,the levels of CD4+and CD4+/CD8+in the combination group were obviously higher than those in the control group(P＜0.05),while the level of CD8+was obviously lower than that in the control group(P＜0.05).There was no obvious difference in the occurrence of adverse reactions between the two groups(P＞0.05).Conclusion:The combination therapy of TACE and apatinib is effective and has high clinical application value for patients with mid to late stage liver cancer.
liver cancertransarterial chemoembolisationapatinibobjective response rateimmune functionsurvival time
NETL
NSTL
万方数据
维普
